Literature DB >> 11831399

Evaluation of crossed cerebellar diaschisis in 30 patients with major cerebral artery occlusion by means of quantitative I-123 IMP SPECT.

N Miyazawa1, K Toyama, A S Arbab, K Koizumi, T Arai, H Nukui.   

Abstract

Quantitative crossed cerebellar diaschisis (CCD) and the correlation with a reduction in supratentorial regional cerebral blood flow (rCBF) and cerebrovascular reserve capacity (CVR) were investigated in clinically stable patients with major cerebral artery occlusion by the iodine-123-N-isopropyl-p-iodoamphetamine (I-123 IMP) single photon emission computed tomography (SPECT) method. Thirty patients with major cerebral artery occlusion underwent SPECT by the I-123 IMP autoradiographic method. Regional CBF was measured in the cerebral hemisphere, frontal and parietal lobes, temporo-parietal lobe, and cerebellum both at rest and after administration of acetazolamide. Eighteen of 30 patients (60%) had CCD. CCD was significantly related to magnetic resonance imaging evidence of infarction. Quantitative CCD was 17% and the CVR in the cerebellum was preserved in patients with CCD. There was a significant difference in CBF and CVR between the affected and normal sides in all regions of interest in the patients without CCD [CBF (ml/100 g/min): hemisphere (H), normal side (N): 31.4 +/- 6.8, affected side (A): 27.5 +/- 7.4; p < 0.05. CVR: H, N: 0.56 +/- 0.38, A: 0.42 +/- 0.18; p < 0.01]. CCD is common in patients with major cerebral artery occlusion, and quantitative I-123 IMP SPECT is helpful in detecting CCD in clinically stable patients with occlusion of major cerebral arteries.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11831399     DOI: 10.1007/bf02988504

Source DB:  PubMed          Journal:  Ann Nucl Med        ISSN: 0914-7187            Impact factor:   2.668


  7 in total

1.  Ataxic hemiparesis from strategic frontal white matter infarction with crossed cerebellar diaschisis.

Authors:  Alexander C Flint; MaryAlice C Naley; Clinton B Wright
Journal:  Stroke       Date:  2005-11-23       Impact factor: 7.914

2.  Homonymous Visual Field Loss without Structural Lesion on Magnetic Resonance Imaging: Documented with Positron Emission Tomography and Diffusion Tensor Imaging.

Authors:  Tae-Ho Yang; Sun-Young Oh; Kichang Kwak; Jong-Min Lee
Journal:  Neuroophthalmology       Date:  2014-07-22

3.  Decreased fractional anisotropy of middle cerebellar peduncle in crossed cerebellar diaschisis: diffusion-tensor imaging-positron-emission tomography correlation study.

Authors:  Jinna Kim; Seung-Koo Lee; Jong Doo Lee; Yong Wook Kim; Dong Ik Kim
Journal:  AJNR Am J Neuroradiol       Date:  2005-10       Impact factor: 3.825

4.  Remote effects in the ipsilateral thalamus and/or contralateral cerebellar hemisphere using FDG PET in patients with brain tumors.

Authors:  Hitomi Iwasa; Yoriko Murata; Miki Nishimori; Kana Miyatake; Michiko Tadokoro; Shino Kohsaki; Munenobu Nogami; Yusuke Ueba; Tetsuya Ueba; Takuji Yamagami
Journal:  Jpn J Radiol       Date:  2018-01-25       Impact factor: 2.374

5.  Correlation of Asymmetry Indices Measured by Arterial Spin-Labeling MR Imaging and SPECT in Patients with Crossed Cerebellar Diaschisis.

Authors:  K M Kang; C-H Sohn; B S Kim; Y I Kim; S H Choi; T J Yun; J-h Kim; S-W Park; G J Cheon; M H Han
Journal:  AJNR Am J Neuroradiol       Date:  2015-07-30       Impact factor: 3.825

6.  Crossed cerebellar diaschisis-related supratentorial hemodynamic and metabolic status measured by PET/MR in assessing postoperative prognosis in chronic ischemic cerebrovascular disease patients with bypass surgery.

Authors:  Bixiao Cui; Yi Shan; Tianhao Zhang; Yan Ma; Bin Yang; Hongwei Yang; Liqun Jiao; Baoci Shan; Jie Lu
Journal:  Ann Nucl Med       Date:  2022-07-05       Impact factor: 2.258

7.  Quantifying cerebellum grey matter and white matter perfusion using pulsed arterial spin labeling.

Authors:  Xiufeng Li; Subhendra N Sarkar; David E Purdy; Richard W Briggs
Journal:  Biomed Res Int       Date:  2014-05-15       Impact factor: 3.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.